Phase 1 21 trials
Phase 1
NCT04250545 Oct 2020 → Nov 2025 overdue metastatic malignant neoplasm in the brain , neoplastic meningitis , non-small cell lung carcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04479306 Jun 2020 → Jul 2023 non-small cell lung carcinoma M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT03017833 Mar 2018 → Dec 2022 metastatic malignant neoplasm M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT03430882 Mar 2018 → Jun 2022 refractory malignant neoplasm , secondary malignant neoplasm M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT03205891 Mar 2018 → Mar 2021 anaplastic large cell lymphoma , classic Hodgkin lymphoma , peripheral T-cell lymphoma, not otherwise specified M.D. Anderson Cancer Center
Withdrawn
No outcome recorded
Phase 1
NCT03370302 Jan 2018 → Aug 2019 neoplasm Calithera Biosciences, Inc
Terminated
No outcome recorded
Phase 1
NCT03154294 Jul 2017 → Nov 2020 —
Avera McKennan Hospital & University Health Center
Completed
No outcome recorded
Phase 1
NCT02619669 Apr 2017 → Jun 2019 female breast carcinoma Gary Schwartz
Withdrawn
No outcome recorded
Phase 1
NCT02503722 Mar 2017 → Feb 2027 expected non-small cell lung carcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT02812056 Sep 2016 → Sep 2021 digestive system cancer , female reproductive organ cancer , head and neck cancer , male reproductive organ cancer M.D. Anderson Cancer Center
Withdrawn
No outcome recorded
Phase 1
NCT02719691 May 2016 → Mar 2020 breast cancer University of Colorado, Denver
Completed
No outcome recorded
Phase 1
NCT02412722 Mar 2015 → May 2018 cancer-related condition Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 1
NCT02327169 Jan 2015 → Jul 2018 neoplastic disease or syndrome Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 1
NCT02197572 Sep 2014 → Jun 2016 cancer Calithera Biosciences, Inc
Completed
No outcome recorded
Phase 1
NCT02133183 Jul 2014 → Jan 2020 gliosarcoma National Cancer Institute (NCI)
Terminated
No outcome recorded
Phase 1
NCT02159989 Jun 2014 → Jun 2021 fibrolamellar hepatocellular carcinoma , metastatic malignant neoplasm , ovarian carcinoma , pancreatic neuroendocrine tumor National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT02142803 May 2014 → Dec 2020 overdue adult glioblastoma , endometrial clear cell adenocarcinoma , endometrial serous adenocarcinoma , fallopian tube carcinoma +5 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT01899053 Jun 2013 → Jan 2017 neoplasm Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 1
NCT01351350 Feb 2011 → Sep 2017 hematopoietic and lymphoid cell neoplasm , high grade malignant neoplasm Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 1
NCT01118689 Nov 2010 → May 2013 Waldenstrom macroglobulinemia , plasma cell myeloma Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 1
NCT01058707 Jan 2010 → Feb 2019 —
Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Show 11 more trials Phase 1/2 8 trials
Phase 1/2
NCT07558733 Apr 2026 → May 2029 expected hormone receptor-positive breast cancer Faeth Therapeutics
Recruiting
No outcome recorded
Phase 1/2
NCT06811116 Nov 2025 → Aug 2027 expected hepatocellular carcinoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1/2
NCT05022394 Feb 2021 non-small cell lung carcinoma M.D. Anderson Cancer Center
Withdrawn
No outcome recorded
Phase 1/2
NCT02727777 Mar 2017 → Jul 2018 lymphoma M.D. Anderson Cancer Center
Terminated
No outcome recorded
Phase 1/2
NCT02575339 Jul 2016 → Jun 2018 hepatocellular carcinoma Kathy Miller
Terminated
No outcome recorded
Phase 1/2
NCT02601209 Nov 2015 → Dec 2018 leiomyosarcoma of the corpus uteri , malignant peripheral nerve sheath tumor , myxofibrosarcoma , synovial sarcoma +1 National Cancer Institute (NCI)
Terminated
No outcome recorded
Phase 1/2
NCT02514824 Oct 2015 → Apr 2017 cutaneous neuroendocrine carcinoma Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 1/2
NCT02244463 Jul 2015 → Apr 2022 differentiated thyroid carcinoma , thyroid gland undifferentiated (anaplastic) carcinoma Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 2 23 trials
Phase 2
NCT06463028 Dec 2024 → Sep 2028 expected endometrial cancer Faeth Therapeutics
Recruiting
No outcome recorded
Phase 2
NCT05275673 Jul 2022 → Jan 2023 non-small cell squamous lung carcinoma Faeth Therapeutics
Terminated
No outcome recorded
Phase 2
NCT04267913 Sep 2020 → Oct 2025 squamous cell lung carcinoma SWOG Cancer Research Network
Withdrawn
No outcome recorded
Phase 2
NCT03648489 Sep 2018 → Nov 2023 fallopian tube carcinoma , ovarian carcinosarcoma , ovarian clear cell adenocarcinoma , ovarian endometrioid adenocarcinoma +2 Imperial College London
Completed
No outcome recorded
Phase 2
NCT03745911 May 2018 → Nov 2020 urothelial carcinoma Associació per a la Recerca Oncologica, Spain
Unknown
No outcome recorded
Phase 2
NCT03047213 Aug 2017 → Oct 2020 overdue urinary bladder carcinoma , urothelial carcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT03097328 Aug 2017 → Jul 2021 renal cell carcinoma Bradley A. McGregor, MD
Completed
No outcome recorded
Phase 2
NCT03193853 Jul 2017 → Mar 2020 triple-negative breast carcinoma Joyce O'Shaughnessy
Completed
No outcome recorded
Phase 2
NCT02893930 Apr 2017 → May 2021 pancreatic endocrine carcinoma , pancreatic neuroendocrine tumor G1 National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 2
NCT02988986 Apr 2017 → Feb 2019 estrogen-receptor positive breast cancer The Methodist Hospital Research Institute
Completed
No outcome recorded
Phase 2
NCT02484430 Apr 2017 → Dec 2018 B-cell acute lymphoblastic leukemia , B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) , T-cell acute lymphoblastic leukemia , adult acute lymphoblastic leukemia National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 2
NCT06385496 Mar 2017 → Dec 2026 expected adult lymphoma , plasma cell myeloma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT06390865 Mar 2017 → Dec 2026 expected plasma cell myeloma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT02987959 Feb 2017 → Jan 2019 soft tissue sarcoma Fox Chase Cancer Center
Terminated
No outcome recorded
Phase 2
NCT02417701 Oct 2016 → Dec 2020 non-small cell squamous lung carcinoma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 2
NCT02756364 Jul 2016 → Nov 2019 breast neoplasm Calithera Biosciences, Inc
Completed
No outcome recorded
Phase 2
NCT02724020 Jun 2016 → Feb 2020 clear cell renal carcinoma Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 2
NCT02725268 Apr 2016 → Jul 2019 endometrial cancer Millennium Pharmaceuticals, Inc.
Completed
No outcome recorded
Phase 2
NCT02465060 Aug 2015 → Dec 2026 expected breast carcinoma , carcinoma of esophagus , cervical carcinoma , colon carcinoma +17 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 2
NCT02091531 Mar 2014 → Oct 2018 prostate carcinoma Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 2
NCT02049957 Feb 2014 → Jun 2018 female breast carcinoma Calithera Biosciences, Inc
Completed
No outcome recorded
Phase 2
NCT00756041 Sep 2005 → Sep 2006 diabetic neuropathy Takeda
Terminated
No outcome recorded
Phase 2
NCT00229437 Mar 2005 → May 2006 diabetic neuropathy Takeda
Completed
No outcome recorded
Show 13 more trials